HYAL-AT2101 topical non-steroidal anti-inflammatory delivered with a hyaluronic acid formulation data

HYALF (Mississauga, Ontario) presented Phase III results showing significant pain relief (p < 0.0001), and reductions in morning stiffness and tenderness, as well as an improved global efficacy assessment (all significant at p < 0.005 or more), compared to placebo. ...